drugset / Trial / NCT06747338
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This randomized, controlled, open-label, multicenter study will evaluate the safety and efficacy of KN026 in combination with HB1801 ± Carboplatin as neoadjuvant therapy in patients with early or locally advanced HER2-positive breast cancer.
Timeline
- Start
- 2024-12-16
- Primary completion
- 2026-12-16
- Completion
- 2027-12-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carboplatin | Small molecule | — | — |
| Comparator | Docetaxel | Small molecule | — | — |
| Subject | HB1801 | Unknown | — | — |
| Subject | KN026 | Monoclonal antibody | — | — |
| Comparator | Pertuzumab | Monoclonal antibody | — | — |
| Comparator | Trastuzumab | Monoclonal antibody | — | — |